Persistent clinical efficacy and safety of infliximab in ankylosing spondylitis after 8 years--early clinical response predicts long-term outcome
Open Access
- 14 June 2011
- journal article
- research article
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 50 (9), 1690-1699
- https://doi.org/10.1093/rheumatology/ker194
Abstract
Objectives. To report for the first time on the efficacy and safety of anti-TNF therapy after 8 years of follow-up in patients with active AS, and analyse possible short-term predictors for long-term clinical outcomes. Methods. In this open-label extension of a randomized controlled trial, proportions of the initially included 69 patients with active AS were treated with infliximab 5 mg/kg i.v./6 weeks for 8 years. The last report was published after 5 years. All analyses were based on completers. Results. Overall, 33 (48%) patients completed 8 years. Their mean (s.d.) BASDAI [2.6 (1.9)], BASFI [3.3 (2.6)] and BASMI [2.7 (2.4)] remained low at Year 8. At the end of Year 8, most patients were either in partial remission (n = 8, 24%) or had low disease activity (BASDAI < 3; n = 21, 64%). No new serious adverse events occurred within the past 3 years. Adverse events were the most frequent reason for dropout (56%). There were no differences between completers and dropouts at baseline, but the latter had higher BASFI values at dropout. No baseline parameter was associated with good long-term response to infliximab, but lower BASDAI levels after 12 weeks were predictive of a higher probability of partial remission [odds ratio (OR) 2.9, 95% CI 1.3, 6.3, P = 0.007], low disease activity (OR 1.7, 95% CI 1.2, 2.3, P = 0.005) or remaining on treatment (OR 0.79, 95% CI 0.61, 1.01, P = 0.06) after 8 years. Conclusion. Almost half of the initially treated patients remained on anti-TNF therapy for 8 years, and almost 90% were in partial remission or had low disease activity. Short-term response (low BASDAI at 3 months) is predictive of outcome after 8 years. Infliximab therapy was safe over 8 years.Keywords
This publication has 40 references indexed in Scilit:
- Switching from infliximab or etanercept to adalimumab in resistant or intolerant patients with spondyloarthritis: a 4-year studyRheumatology, 2010
- Assessment of radiographic progression in the spines of patients with ankylosing spondylitis treated with adalimumab for up to 2 yearsArthritis Research & Therapy, 2009
- Efficacy and safety of golimumab in patients with ankylosing spondylitis: Results of a randomized, double‐blind, placebo‐controlled, phase III trialArthritis & Rheumatism, 2008
- Radiographic progression of ankylosing spondylitis after up to two years of treatment with etanerceptArthritis & Rheumatism, 2008
- Persistent clinical efficacy and safety of anti-tumour necrosis factor therapy with infliximab in patients with ankylosing spondylitis over 5 years: evidence for different types of responseAnnals Of The Rheumatic Diseases, 2007
- Progression of radiographic damage in patients with ankylosing spondylitis: defining the central role of syndesmophytesAnnals Of The Rheumatic Diseases, 2007
- Nonsteroidal anti-inflammatory drug use in ankylosing spondylitis—a population-based surveyClinical Rheumatology, 2006
- Sustained durability and tolerability of etanercept in ankylosing spondylitis for 96 weeksAnnals Of The Rheumatic Diseases, 2005
- The burden of ankylosing spondylitis and the cost-effectiveness of treatment with infliximab (Remicade(R))Rheumatology, 2004
- A Nonparametric Test for Random DropoutsBiometrical Journal, 2003